Cardiac Rhythm Management

Author Guidelines

Download the Complete Author Guidelines Pack

Print ISSN: 2156-3977
Online ISSN: 2156-3993

General Information

Journal of Innovations in Cardiac Rhythm Management has been in continuous publication since 2010, is an international open access double blind peer-reviewed clinical journal published 12 times per year. The Editor in Chief of JICRM is Moussa Mansour, MD. JICRM has complete editorial independence of its owner and publisher, MediaSphere Medical, LLC.

JICRM is a widely circulated journal in the latest developments impacting the field of cardiac arrhythmia management, including advancements in device therapy and evolutions within electrophysiology in the world. The print and online version is made freely available.

Manuscripts should be submitted online via the JICRM online manuscript submission and review system at http://www.editorialmanager.com/innovationsincrm. For more information, see Manuscript Submission.

Editorial Office Contact Information

Aliza Becker, Managing Editor, MediaSphere Medical, LLC, 1101 North Kings Highway, Suite 440, Cherry Hill, NJ 08034, USA; Telephone: 856-320-6297; Fax: (856) 438-6760; E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Indexing Services
CrossRef, Google Scholar, National Library of Medicine, OCLC WorldCat

Affiliated Societies
Journal of Innovations in Cardiac Rhythm Management is affiliated with the Inter-American Society of Cardiology (SIAC) and the Latin American Society of Cardiac Stimulation and Electrophysiology (SOLAECE).

Aims and Scope
The Journal of Innovations in Cardiac Rhythm Management is a clinical journal that publishes peer-reviewed articles on the latest developments impacting the field of cardiac arrhythmia management, including advancements in device therapy and evolutions within electrophysiology. Suitable articles related to the management of complex cardiac arrhythmias, heart failure, and sudden cardiac arrest that document the state of current practice will be considered.

Ethics in Publishing

More information
JICRM is committed to maintaining the highest standards of publication ethics and to supporting ethical research practices. The journal adheres to the Committee on Publication Ethics (COPE) (http://publicationethics.org/) Code of Conduct for Journal Publishers. We encourage journal editors to follow the COPE Code of Conduct for Journal Editors and to refer reviewers to the COPE Ethical Guidelines for Peer Reviewers as appropriate. Allegations of misconduct will be investigated in accordance with the COPE Best Practice Guidelines. If notified of a potential breach of publication ethics, we encourage journal editors and staff to inform JICRM as soon as possible. JICRM staff is trained on how to proceed with investigations into allegations of ethical misconduct and will seek legal counsel when necessary. Authors may use the free tool EthicsGen at http://www.ethicsgen.com/ to generate the ethics statement for their manuscripts.

Authorship

More information
Authorship confers credit and has important academic, social, and financial implications. Authorship also implies responsibility and accountability for published work. Authors that meet all four authorship criteria of the International Committee on Medical Journal Ethics (ICJME) requirements for authorship should be included as an author of the manuscript. Those contributors that meet fewer than the four authorship criteria should not be listed as authors. They should be included in the Acknowledgements section of the manuscript, which must be provided under the subheading ‘Acknowledgements’. All submissions are expected to comply with the ICMJE authorship definition. Changes to the authorship list after submission will result in a query from the publisher requesting written explanation.

Conflict of Interest Statement

More information
All authors must disclose detailed information about all relevant financial interests, activities, relationships, and affiliations (other than those affiliations listed in the title page of the manuscript) including, but not limited to, employment, affiliation, funding and grants received or pending, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

The corresponding author is required to sign and submit the ICMJE Form for Disclosure of Potential Conflicts of Interest. Note: This form will be required via the JICRM online manuscript submission system but authors should also include conflict of interest disclosures and Acknowledgements sections in the submitted manuscript.

Funding/Support and Role of Funder/Sponsor

More information
At the time of submission, information on the funding source must also be completed via the JICRM online manuscript submission and review system. The specific role of the funding organization or sponsor in each of the following should be specified: “design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.”

Ethical Approval of Studies and Informed Consent

More information
For all manuscripts reporting data from studies involving human participants or animals, formal review and approval, or formal review and waiver, by an appropriate institutional review board or ethics committee is required and should be described in the Methods section. For those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. For investigations of humans, state in the Methods section the manner in which informed consent was obtained from the study participants (i.e., oral or written) and whether participants received a stipend. Editors may request that authors provide documentation of the formal review and recommendation from the institutional review board or ethics committee responsible for oversight of the study.

The Patient Consent form for publication of identifying material is available here.

Statement of Human and Animal Rights

More information
When reporting studies that involve human participants, authors should include a statement that the studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that the independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study.

The welfare of animals used for research must be respected. When reporting experiments on animals, authors should indicate whether the international, national, and/or institutional guidelines for the care and use of animals have been followed, and that the studies have been approved by a research ethics committee at the institution or practice at which the studies were conducted (where such a committee exists).

When describing surgical procedures on animals, identify the pre anesthetic and anesthetic agents used and state the amount of concentration and the route and frequency of administration for each. The use of paralytic agents, such as curare or succinylcholine, is not an acceptable substitute for anesthetics. For other invasive procedures on animals, report the analgesic or tranquilizing drugs used; if none were used, provide justification for such exclusion. When reporting studies on unanaesthetized animals or on humans, indicate that the procedures followed were in accordance with institutional guidelines.

Submission Declaration

More information
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder. Please confirm in the Title Page with submission that the manuscript is original and that all authors are responsible for the contents and have read and approved the manuscript for submission to JICRM.

Clinical Trials

More information
In accordance with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardize consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

Clinical Trials Registry

More information
Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors (ICMJE, External link http://www.icmje.org) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. The registry must be accessible to the public at no charge, be open to all prospective registrants and managed by a not-for-profit organization. For a list of registries that meet all of these requirements, please see the WHO International Clinical Trials Registry Platform (ICTRP). A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Copyright, Permissions and Author Rights

More information
Authors are responsible for obtaining permissions to use material owned by others. Since the permission-seeking process can be time-consuming, it is wise to request permission as soon as possible. Permissions can be requested through Copyright Clearance Center. If further assistance is needed, please contact the This e-mail address is being protected from spambots. You need JavaScript enabled to view it directly. Please keep the originals for record. 

JICRM is entirely open access, without any submission, subscription, page, color, cover or open access charges to authors, due to sponsorship. The review process is stringent and efficient. A properly completed and signed Publishing Agreement must be submitted for each manuscript upon submission. Upon publication, authors’ articles are immediately openly accessible. Deposit of the final article into a repository of the author’s choosing is also available at no charge.

Authors who prefer or must publish articles under the terms of a Creative Commons Attribution-NonCommercial license can request further information from the Editorial Office about the Creative Commons CC BY-NC 4.0 license.

NIH/Wellcome-funded authors must submit their funded work to PMC/Europe PMC themselves providing they submit only the final peer-reviewed manuscript which was accepted for publication (post-print) (this manuscript must not be altered by copyediting and typesetting services) and stating the 12-month (NIH) or 6-month (Wellcome Trust) embargo period after final publication.

Advertising Policy

More information
JICRM is not dominated by advertisements, and advertising does not influence editorial decisions. The journal prohibits selling advertisements intended to be juxtaposed with editorial content on the same product. Advertisements are clearly identifiable as advertisements. Editors have full and final authority for approving print and online advertisements and for enforcing advertising policy.

JICRM does not carry advertisements for products proven to be seriously harmful to health. Editors ensure that existing regulatory or industry standards for advertisements are enforced. The interests of organizations or agencies do not control classified and other non-display advertising, except where required by law. Editors consider all criticisms of advertisements for publication.

Peer Review Process

More information
JICRM manuscripts are reviewed by two independent experts in the relevant area. The reviewers make a scientific assessment and a recommendation to the editors. Reviewers remain unknown to authors. The Handling editor considers the manuscript and the reviewers’ comments before making a final decision. JICRM expects editors and reviewers to handle all submissions in confidence. Editors have full editorial independence. JICRM will never knowingly exert pressure on editors to accept manuscripts for commercial or political reasons.

JICRM provides the option for submitting authors to suggest preferred reviewers. It is the responsibility of the lead author to ensure that only genuine reviewers and reviewer contact details are put forward. Any suspected or alleged instances of authors submitting fabricated reviewer details will be thoroughly investigated. If such allegations are proven, the article in question will be immediately rejected or, if already published, retracted. The journal would typically notify the authors’ institutional or local ethics council.

Journal requirements for independent data analysis and for public data availability are as follows:
Editors may request a statistical analysis of trial data by an independent biostatistician before accepting studies for publication. Authors should state whether the study data are available to third parties to view and/or use/reanalyze. Editors may encourage or require authors to share their data with others for review or reanalysis.

The journal encourages readers to submit comments, questions, or criticisms about published articles and authors have a responsibility to respond appropriately and cooperate with any requests from the journal for data or additional information should questions about the paper arise after publication.

Submission of Manuscripts

More information
Please use the Manuscript Checklist to ensure that your manuscript is complete and in compliance with the Author Guidelines. Please check the following points before approving the PDF file for your manuscript. Manuscripts that do not conform may be returned for correction and resubmission.

Manuscript Types

Please use the Manuscript Types Table for complete details.

  • Original Research
  • Review
  • Complex Case Study
  • Fellows Innovations
  • Unique Image Review
  • Interesting Electrocardiograms
  • Expert Commentaries (Invitation Only)
  • Expert Insights (Invitation Only)
  • Controversies in Electrophysiology (Invitation Only)
  • Step-Wise Approaches
  • Innovative Technique and Technology Features
  • Letters to the Editor

Manuscript Structure

Title Page

  • Total word count (does not include references, acknowledgement, figures and tables)
  • Full Title (does not exceed 50 words – bold centered)
  • Short Title (does not exceed 20 words)
  • Authors
    • Each author’s highest academic degrees should be listed and the name of the department(s) and institution(s) or organizations where the work was conducted. i.e. Martha A. Smith, MD1
    • Authors names (in a row, first name, last name, academic degree) i.e. Martha A. Smith, MD1
    • Institutions (1,2,3… and department of.., institution, city, state, country) i.e. 1Department of Cardiology, University of Pennsylvania, Philadelphia, PA, US
  • Corresponding Author
    • One author has been designated as the corresponding author with contact details:
      • E-mail address
      • Full postal address
      • Phone numbers
  • Keywords (does not exceed 5 keywords)
    • Optimally, these key words should be selected with the assistance of the National Library of Medicine’s medical subject headings (MeSH) browser, available at www.nlm.nih.gov/mesh/MBrowser.html.
  • Structured abstract (does not exceed 350 words)
    • Background
    • Objectives
    • Methods
    • Results
    • Conclusion
  • Disclosure of Funding Statement (see Funding/Support and Role of Funder/Sponsor for more information)
    • Authors should report how the article is funded, and specifically, the disclosure of any and all pharmaceutical company funding (partial or total) OR a statement that there was no involvement of a pharmaceutical/other company (if this is the case). The specific role of the funding organization or sponsor in each of the following should be specified: “design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.”
  • Conflict of Interest Statement (see Conflict of Interest for more information)
    • Must include all authors.
    • All authors must disclose detailed information about all relevant financial interests, activities, relationships, and affiliations (other than those affiliations listed in the title page of the manuscript) including, but not limited to, employment, affiliation, funding and grants received or pending, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
    • Authors without conflicts of interest, including relevant financial interests, activities, relationships, and affiliations, should indicate such and include a statement of no such interests.
  • Submission Declaration Statement (see Submission Declaration for more information)
    • Please confirm in the title page with submission that the manuscript is original, with no portion under simultaneous consideration for publication elsewhere or previously published, and that all authors are responsible for the contents and have read and approved the manuscript for submission to JICRM.
  • Ethics Statement (see Ethical Approval of Studies and Informed Consent for more information)
    • Authors may use the free tool EthicsGen at http://www.ethicsgen.com/ to generate the ethics statement for their manuscripts.
  • Acknowledgments and Permissions (see Copyright, Permissions and Author Rights for more information)
    • Acknowledgements should be brief, and should not include thanks to anonymous referees and editors, or effusive comments. Grant or contribution numbers may be acknowledged.
    • Illustrations and tabulated data from other publications must be acknowledged and must have received permission from the previous publisher. Provide the following information where applicable: author(s), title of article or chapter, title of journal or book, volume number, page number(s), month and year of publication, and publisher name and location. The publisher’s permission to reprint or adapt text or graphics must be submitted with the manuscript.
    • A properly completed and signed Publishing Agreement must be submitted for each manuscript upon submission.

Main Text

  • Introduction
  • Materials and Methods
  • Results
  • Discussion
  • Study limitations
  • Conclusion
  • References (AMA 10th edition style)
  • References should be numbered sequentially, first throughout the text, then in tables, followed by figures.
  • List all authors and/or editors up to 6; if more than 6, list the first 3 followed by "et al."

Examples of reference style:

Journal Article

  • Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficileinfection. JAMA. 2014;312(17):1772-1778.
  • Nicholson WJ, Tuohy KA, Tilkemeier P, et al. Twiddler’s syndrome. N Engl J Med. 2003;348(17):1726–1727.

Online Only Journal Article

  • Murray CJL. Maximizing antiretroviral therapy in developing countries: the dual challenge of efficiency and quality [published online December 1, 2014]. JAMA. doi:10.1001/jama.2014.16376

Electronic Resource (For more examples of electronic references, click here.)

  • Centers for Medicare & Medicaid Services. CMS proposals to implement certain disclosure provisions of the Affordable Care Act. http://www.cms.gov/apps/media/press/factsheet.asp?Counter=4221. Accessed January 30, 2012.

Book

  • McPhee SJ, Winker MA, Rabow MW, Pantilat SZ, Markowitz AJ, eds. Care at the Close of Life: Evidence and Experience. New York, NY: McGraw Hill Medical; 2011.

Figures

  • Figures submitted (line drawings, halftones, photos, graphics, etc.) should be digital files that follow these guidelines:
    1. High-resolution TIFF, EPS or PSD files
      1. ≥350 ppi
      2. ≥1200 ppi for line art
    2. Figure legends (should be no more than 50 words) should be typed separately from the figures and placed in the main text document after the References section.
    3. Each figure must be numbered and cited in the text.
    4. File naming – figures should be saved as clearly named files so that they can easily be identified in terms of manuscript, figure number, and format, i.e. Fig 1.tif.
    5. Include magnification, stain, and other pertinent data where applicable.

Tables

  • Tables must be self-explanatory and supplement, not duplicate the text.
  • Number brief titles in Arabic numerals according to the order they are mentioned in the text.
  • Each table should be typed on a separate page and designed for economy of space and readability.
  • Notes designated in the tables and all abbreviations should be defined in a footnote. Abbreviations should be identified in alphabetical order. i.e. Abbreviations: AF, atrial fibrillation; NA, not available.
  • The axis titles should be bold Arial, 12 pt.  The axis labels should be Arial, 11 pt (not bold). All other labelling must be clear and legible.

Drug Names and Dosing Information

  • Use the generic drug name in text and include in parentheses any trade names that would be more recognizable to clinicians. Drug-dosing information should include dose, frequency, route, and length of time the drug was administered.

Manufacturer Information for Equipment, Devices, and Reagents

  • Proprietary names should be given at first mention along with the nonproprietary name.
  • Authors must include the manufacturer or supplier and location in parentheses after the name or description.
    1. i.e. VAX 3100 workstation (Digital Equipment, Marlboro, MA)

English Language Services: Upon request, MediaSphere Medical will direct authors to an agent who can check and improve the English of their paper (before submission). Please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it for further information.

Editorial Manager Instructions

More information
To log onto Editorial Manager, you must first have an online account. Please go to www.editorialmanager.com/innovationsincrm, enter your username and password, and choose ‘author’. If you have not used the system before, please click the ‘register now’ button and follow the prompts to create a new account. You will be sent your new username and password via email. Please contact the Managing Editor, Aliza Becker via email at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by phone at 856-320-6297 with any questions.

After logging into your account, select ‘submit new manuscript’, select the article type from the pull-down menu and enter your article title. A list of submission steps will appear on the left-hand side of your submission form. The mandatory fields are indicated in red. The final submission step is to upload the text files and digital figures that will be converted to a PDF for use by reviewers. These files must be free of author names, institutions and contact information. Figures MUST NOT include identifying patient information.

After you have attached all of your submission items, click on the ‘build PDF for my approval’ button. You will be directed to your ‘submissions waiting for author approval’ folder. You will be notified when your PDF is built and ready for approval. Once the PDF is built, click on the ‘view submission’ action link. This link opens your PDF. After you have reviewed your PDF, please close it and click on the ‘approve submission’ action link. Your submission will now be sent to the Journal of Innovations in Cardiac Rhythm Management.

Contacting the Publisher

For any questions about the editorial policy or manuscript submissions, please contact:

Aliza Becker, Managing Editor
MediaSphere Medical, LLC
1101 North Kings Highway, Suite 440
Cherry Hill, NJ 08034
856-320-6297

This e-mail address is being protected from spambots. You need JavaScript enabled to view it
mediasphere medical logo